Aleksander Salomon-Perzyński1, Adam Walter-Croneck2, Lidia Usnarska-Zubkiewicz3, Dominik Dytfeld4, Patrycja Zielińska5, Małgorzata Wojciechowska6, Jadwiga Hołojda7, Paweł Robak8, Anna Pasternak9, Wanda Knopińska-Posłuszny9, Dorota Hawrylecka10, Marcin Wójtowicz11, Agnieszka Szeremet3, Michał Osowiecki12, Monika Mordak-Domagała13, Jan Maciej Zaucha14, Krzysztof Giannopoulos15, Krzysztof Warzocha16, Krzysztof Jamroziak16. 1. Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland. Electronic address: salomon.perzynski@gmail.com. 2. Department of Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland. 3. Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland. 4. Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland. 5. Department of Hematology and Bone Marrow Transplantation, School of Medicine in Katowice, Katowice, Poland. 6. Department of Hematology, State Hospital, Olsztyn, Poland. 7. Department of Hematology, Voivodal Specialist Hospital in Legnica, Legnica, Poland. 8. Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland. 9. Department of Hematology, Ministry of the Interior Hospital in Olsztyn with Warmia and Masuria Oncology Centre, Olsztyn, Poland. 10. Department of Hematooncology, Podkarpacie Oncological Center, Brzozów, Poland. 11. Department of Hematology, Regional Hospital in Opole, Opole, Poland. 12. Department of Lymphoid Malignancies, Maria Sklodowska-Curie Institute and Oncology Center, Warsaw, Poland. 13. Lower Silesian Centrum for Cellular Transplantation, Wroclaw, Poland. 14. Department of Hematology and Transplantology, Medical University of Gdansk, Poland; Gdynia Oncology Center, Gdynia, Poland. 15. Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland; Department of Hematology, St. John's Cancer Center, Lublin, Poland. 16. Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Abstract
PURPOSE: Daratumumab is a promising new agent for relapsed/refractory multiple myeloma (RRMM). However, there are limited data on its clinical activity and tolerability in the real-world patients. The purpose of this study is to determine the efficacy and toxicity profile of daratumumab monotherapy in the real-life setting. PATIENTS AND METHODS: Thirty RRMM patients treated with daratumumab who had previously received at least three treatment lines including a proteasome inhibitor and an immunomodulatory drug or had been double refractory (DRMM) were included to the Polish Myeloma Group observational study. RESULTS: The objective response rate to daratumumab was 42.8%. Median progression-free survival (PFS) and overall survival reached 9.5 and 13.8 months, respectively. Importantly, patients with DR-MM had a significantly shorter PFS than other patients (median PFS of 4.1 vs. 12.1 months). Daratumumab was generally well tolerated, however two patients had their therapy interrupted due to adverse events. CONCLUSION: Daratumumab monotherapy has significant activity and good tolerance in heavily pretreated RRMM patients.
PURPOSE:Daratumumab is a promising new agent for relapsed/refractory multiple myeloma (RRMM). However, there are limited data on its clinical activity and tolerability in the real-world patients. The purpose of this study is to determine the efficacy and toxicity profile of daratumumab monotherapy in the real-life setting. PATIENTS AND METHODS: Thirty RRMM patients treated with daratumumab who had previously received at least three treatment lines including a proteasome inhibitor and an immunomodulatory drug or had been double refractory (DRMM) were included to the Polish Myeloma Group observational study. RESULTS: The objective response rate to daratumumab was 42.8%. Median progression-free survival (PFS) and overall survival reached 9.5 and 13.8 months, respectively. Importantly, patients with DR-MM had a significantly shorter PFS than other patients (median PFS of 4.1 vs. 12.1 months). Daratumumab was generally well tolerated, however two patients had their therapy interrupted due to adverse events. CONCLUSION:Daratumumab monotherapy has significant activity and good tolerance in heavily pretreated RRMM patients.
Authors: Han Sae Kim; Jin Ho Lee; Dong Yeol Lee; Hee Yeoun Kim; Dong Han Kim; Joon Seok Oh; Yong Hun Sin; Joong Kyung Kim; Seun Deuk Hwang Journal: Korean J Transplant Date: 2020-06-30